Hoffmann J J, Van Rey F J, Bonnier J J
Thromb Res. 1985 Mar 1;37(5):567-72. doi: 10.1016/0049-3848(85)90089-1.
The effects of BRL 26921, an active-site acylated streptokinase-plasminogen complex, on the fibrinolytic and coagulation systems were studied in 13 patients treated for acute myocardial infarction with a short intravenous infusion of 30 mg of the new drug. In 12/13 patients (92%) significant changes were observed in the concentrations of fibrinogen, fibrin(ogen) degradation products, plasminogen, alpha 2-antiplasmin and F VIII:C; all changes indicating a substantial degree of systemic fibrinolysis. In only one patient were no signs of systemic activation of the fibrinolytic system observed. The therapeutic efficacy of the drug was 85% in this study.
